Lista de obras - Javier de la Rubia - Dominio Público Uruguay

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.

artículo científico

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

scientific article published on 08 July 2008

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.

artículo científico publicado en 2010

Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors.

artículo científico publicado en 2002

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

artículo científico publicado en 2012

Anaphylactic shock and vitamin K1

scientific article published on 01 June 1989

Anemia hemolítica por anticuerpos del sistema ABO o Rh en pacientes receptores de trasplante de órgano sólido

scientific article published on 01 February 2003

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.

artículo científico publicado en 2017

Autologous peripheral blood stem cell transplantation for acute leukaemias

artículo científico publicado en 1999

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

artículo científico publicado en 2015

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

artículo científico publicado en 2011

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

scientific article published on 13 June 2006

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

artículo científico publicado en 2008

Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

artículo científico publicado en 2014

CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors

article

CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma

artículo científico publicado en 2011

Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation.

artículo científico publicado en 2007

Clinical treatment of newly diagnosed multiple myeloma

artículo científico

Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".

scientific article published on March 2014

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.

artículo científico publicado en 2009

Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.

artículo científico publicado en 2014

DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma?

artículo científico publicado en 2010

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

artículo científico publicado en 2016

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

artículo científico publicado en 2017

Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group

artículo científico publicado en 2014

Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.

artículo científico publicado en 2002

Donor age-related differences in PBPC mobilization with rHuG-CSF.

artículo científico publicado en 2001

Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.

artículo científico publicado en 2013

Effect of CD8⁺ cell content on umbilical cord blood transplantation in adults with hematological malignancies

artículo científico publicado en 2014

Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study

artículo científico publicado en 2006

Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study

artículo científico publicado en 2010

European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses.

artículo científico publicado en 2012

European perspective on multiple myeloma treatment strategies in 2014

artículo científico publicado en 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses

artículo científico publicado en 2012

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

artículo científico publicado en 2002

Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation.

artículo científico publicado en 2003

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

artículo científico publicado en 2020

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

artículo científico publicado en 2018

Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry

scientific article published on 02 April 2008

Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.

artículo científico

Further psychometric validation of the GAH scale: Responsiveness and effect size.

artículo científico publicado en 2016

Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma

artículo científico publicado en 2005

Genomic analysis of high-risk smoldering multiple myeloma.

artículo científico publicado en 2012

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2011

Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.

artículo científico publicado en 2009

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

artículo científico publicado en 2015

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

artículo científico publicado en 2020

Immunotherapy for the treatment of Hodgkin lymphoma.

artículo científico publicado en 2017

Impact of the conditioning regimen in patients with multiple myeloma who undergo autologous transplantation

artículo científico publicado en 2011

Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation

scientific article published on 01 January 2014

Incidence of Wra antigen and anti-Wra in a Spanish population

artículo científico publicado en 2005

Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation

artículo científico publicado en 2009

Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?

artículo científico

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

artículo científico publicado en 2008

Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.

artículo científico publicado en 2012

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

artículo científico publicado en 2019

Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study.

artículo científico publicado en 2009

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

artículo científico publicado en 2014

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

artículo científico publicado en 2013

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

artículo científico publicado en 2016

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

artículo científico publicado en 2011

Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study.

artículo científico publicado en 2008

Mild hemolytic disease of the newborn due to anit-Go(a)

artículo científico publicado en 1999

Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation

scientific article published on 01 August 2006

Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials

article

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

artículo científico publicado en 2008

Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.

artículo científico publicado en 2002

Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment

artículo científico publicado en 2009

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

artículo científico publicado en 2014

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

artículo científico publicado en 2015

Pegfilgrastim as adjunct to chemotherapy to mobilize hematopoietic stem cells

artículo científico publicado en 2005

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

artículo científico publicado en 2020

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma.

artículo científico publicado en 2015

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

artículo científico publicado en 2007

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

artículo científico publicado en 2010

Platelet transfusion and thrombotic thrombocytopenic purpura

artículo científico publicado en 2002

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.

artículo científico publicado en 2016

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

scientific article published on 28 April 2008

Quality control of bacterial contamination in autologous peripheral blood stem cells for transplantation.

artículo científico publicado en 2004

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.

artículo científico publicado en 2016

Recent Advances in the Treatment of Patients with Multiple Myeloma

scientific article published on 30 November 2020

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

artículo científico

Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings

artículo científico publicado en 2002

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

scientific article published on 22 April 2019

Second mobilization and collection of peripheral blood progenitor cells in healthy donors is associated with lower CD34(+) cell yields

artículo científico publicado en 2002

Severe hemolytic anemia due to anti-E after renal transplantation

scientific article published on 01 August 1997

Severe hemolytic disease of the fetus due to anti-Jkb

artículo científico publicado en 2008

Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial.

artículo científico publicado en 2009

Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study

artículo científico publicado en 2019

Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia.

artículo científico publicado en 2010

Treatment of intra-abdominal bleeding with recombinant activated factor VII in a patient with disseminated intravascular coagulation secondary to septic shock

artículo científico publicado en 2005

Treatment of multiple myeloma in the elderly: realities and hopes ⬇️

artículo científico publicado el 15 de noviembre de 2010

Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

artículo científico publicado en 2008

Which therapies will move to the front line for multiple myeloma?

artículo científico publicado en 2017

Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

artículo científico publicado en 2015

[Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group]

artículo científico publicado en 2009

[Thrombotic thrombocytopenic purpura]

artículo científico publicado en 2010

Lista de obras de Javier de la Rubia

A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.

Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors.

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Anaphylactic shock and vitamin K1

Anemia hemolítica por anticuerpos del sistema ABO o Rh en pacientes receptores de trasplante de órgano sólido

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.

Autologous peripheral blood stem cell transplantation for acute leukaemias

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors

CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma

Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation.

Clinical treatment of newly diagnosed multiple myeloma

Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia.

Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.

DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma?

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group

Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.

Donor age-related differences in PBPC mobilization with rHuG-CSF.

Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome.

Effect of CD8⁺ cell content on umbilical cord blood transplantation in adults with hematological malignancies

Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study

Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study

European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses.

European perspective on multiple myeloma treatment strategies in 2014

European perspective on multiple myeloma treatment strategies: update following recent congresses

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation.

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry

Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.

Further psychometric validation of the GAH scale: Responsiveness and effect size.

Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma

Genomic analysis of high-risk smoldering multiple myeloma.

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

Immunotherapy for the treatment of Hodgkin lymphoma.

Impact of the conditioning regimen in patients with multiple myeloma who undergo autologous transplantation

Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation

Incidence of Wra antigen and anti-Wra in a Spanish population

Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation

Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma

Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study.

Mild hemolytic disease of the newborn due to anit-Go(a)

Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation

Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.

Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

Pegfilgrastim as adjunct to chemotherapy to mobilize hematopoietic stem cells

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma.

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

Platelet transfusion and thrombotic thrombocytopenic purpura

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy